CCM
PBYI icon

Camber Capital Management’s Puma Biotechnology PBYI Stock Holding History

Camber Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,650,000
Closed -$8.74M – 40
2024
Q1 		$8.74M Sell
1,650,000
-1,155,000
-41% -$6.22M 0.21% 34
2023
Q4 		$12.1M Sell
2,805,000
-1,430,000
-34% -$4.74M 0.31% 32
2023
Q3 		$11.1M Hold
4,235,000
– – 0.37% 35
2023
Q2 		$14.9M Hold
4,235,000
– – 0.49% 32
2023
Q1 		$13.1M Hold
4,235,000
– – 0.4% 34
2022
Q4 		$17.9M Hold
4,235,000
– – 0.61% 30
2022
Q3 		$10M Hold
4,235,000
– – 0.31% 45
2022
Q2 		$12.1M Buy
4,235,000
+235,000
+6% +$584K 0.52% 32
2022
Q1 		$11.5M Buy
4,000,000
+1,950,000
+95% +$5.04M 0.42% 32
2021
Q4 		$6.23M Sell
2,050,000
-1,375,000
-40% -$5.97M 0.21% 34
2021
Q3 		$24M Buy
3,425,000
+700,000
+26% +$5.24M 0.74% 33
2021
Q2 		$25M Buy
2,725,000
+170,000
+7% +$1.72M 0.84% 34
2021
Q1 		$24.8M Hold
2,555,000
– – 0.85% 29
2020
Q4 		$26.2M Hold
2,555,000
– – 0.92% 29
2020
Q3 		$25.8M Buy
2,555,000
+155,000
+6% +$1.58M 1.36% 23
2020
Q2 		$25M Buy
2,400,000
+450,000
+23% +$4.66M 1.43% 19
2020
Q1 		$16.5M Buy
+1,950,000
New +$18.9M 0.98% 24
2019
Q1 		– Sell
-1,300,000
Closed -$26.5M – 36
2018
Q4 		$26.5M Buy
1,300,000
+550,000
+73% +$16.5M 1.26% 29
2018
Q3 		$34.4M Buy
+750,000
New +$36.2M 1.47% 20
2017
Q2 		– Sell
-650,000
Closed -$24.2M – 38
2017
Q1 		$24.2M Buy
+650,000
New +$23.7M 0.98% 25

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Camber Capital Management's PBYI Position: Q2 2024 in Review

Camber Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 1,650,000 shares — an estimated $8.74M sold.

Camber Capital Management first reported a position in PBYI in Q1 2017 and held it in 20 quarters. The position peaked at $34.4M in Q3 2018. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Camber Capital Management reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Camber Capital Management sold 1,650,000 Puma Biotechnology shares in Q2 2024, an estimated $8.74M.
  • Camber Capital Management first reported a position in Puma Biotechnology in Q1 2017 and held it in 20 quarters.
  • Camber Capital Management's Puma Biotechnology position peaked at $34.4M in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Camber Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.